Oral Session 1-8B Pediatric AML

[OS1-8B-3] Comprehensive methylation analysis in pediatric AML patients -the JCCG, JPLSG AML-05 study-

Genki Yamato^1,2,3, Tomoko Kawai⁴, Norio Shiba^3,5, Yusuke Hara^2,3, Kentaro Ohki⁶, Taeko Kaburagi¹, Kenichi Yoshida⁷, Yuichi Shiraishi⁸, Satoru Miyano⁹, Nobutaka Kiyokawa⁶, Daisuke Tomizawa¹⁰, Akira Shimada¹¹, Manabu Sotomatsu¹, Hirokazu Arakawa², Souichi Adachi¹², Takashi Taga¹³, Keizo Horibe³, Seishi Ogawa⁷, Kenichiro Hata⁴, Yasuhide Hayashi^1,3,14 (1.Department of Hematology/Oncology, Gunma Children's Medical Center, Gunma, Japan, 2.Department of Pediatrics, Gunma University, Gunma, Japan, 3.Clinical Research Center, National Hospital Organization Nagoya Medical Center, Aichi, Japan, 4.Department of Maternal-Fetal Biology, NCCHD, Tokyo, Japan, 5.Department of Pediatrics, Yokohama City University Hospital, Kanagawa, Japan, 6.Department of Pediatric Hematology/Oncology Research, NCCHD, Tokyo, Japan, 7.Department of Pathology and Tumor Biology, Kyoto University, Kyoto, Japan, 8.Division of Cellular Signaling, National Cancer Center Research Institute, Tokyo, Japan, 9.Human Genome Center, The University of Tokyo, Tokyo, Japan, 10.Children's Cancer Center, NCCHD, Tokyo, Japan, 11.Department of Pediatrics, Okayama University, Okayama, Japan, 12.Department of Human Health Sciences, Kyoto University, Kyoto, Japan, 13.Department of Pediatrics, Shiga University of Medical Science, Shiga, Japan, 14.Institute of Physiology and Medicine, Jobu University, Gunma, Japan)